A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system

Behav Brain Res. 2016 Jan 15:297:41-50. doi: 10.1016/j.bbr.2015.10.007. Epub 2015 Oct 22.

Abstract

Despite the presence of a multitudinous pharmacotherapy, diabetes-induced depressive disorder remains undertreated. Evidence suggests that brain serotonergic deficits are associated with depressive-like behavior in diabetes and that 5HT3 receptor (5HT3R) antagonists have serotonergic facilitatory effects. This study examined the effects of a novel 5HT3R antagonist, 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide), in diabetes-induced depressive phenotypes. Experimentally, (1) to evaluate the effects of 4i, mice with 8-weeks of diabetes (induced by streptozotocin, 200mg/kg, i.p.) were treated with vehicle, 4i (0.5 and 1mg/kg/day, i.p.), fluoxetine (10mg/kg/day, i.p.) for 4-weeks and subjected to neurobehavioral assays, followed by biochemical estimation of serotonin levels in midbrain, prefrontal-cortex and cerebellum. (2) To evaluate the role of 5HT3R in the postulated effect of 4i, diabetic mice were given 4i (1mg/kg/day, i.p.) after 1h of 1-(m-chlorophenyl)-biguanide (mCPBG, a 5HT3R agonist, 10mg/kg/day, i.p.) treatment and subjected to the same protocol. The results showed that diabetic mice exhibited a significant behavioral deficit, including depression-like behavior in forced swim test, anxiety-like in open field test and sociability deficits in social interaction test, along with a significant decrease in serotonin level in these brain regions. 4i (1mg/kg), similar to fluoxetine, prevented these behavioral abnormalities and normalized brain serotonin levels. 4i (0.5mg/kg) ameliorated only diabetes-induced depressive-like behavior and serotonin deficits, but not anxiety-like effects. mCPBG blunted 4i-mediated behavioral response and increase in brain serotonin levels. Altogether, this study suggests that 4i prevents diabetes-induced depressive phenotypes in mice, which may involve antagonism of 5HT3Rs and increase in serotonin levels in discrete brain regions.

Keywords: 5HT(3) receptor antagonist; Depressive phenotypes; Diabetes; Forced swim test; Open field test; Serotonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / pharmacology*
  • Biguanides / pharmacology
  • Brain / drug effects*
  • Brain / metabolism
  • Depressive Disorder / complications
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / physiopathology
  • Diabetes Mellitus, Experimental / complications*
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetes Mellitus, Experimental / psychology
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Fluoxetine / pharmacology
  • Male
  • Mice
  • Quinoxalines / chemistry
  • Quinoxalines / pharmacology*
  • Random Allocation
  • Receptors, Serotonin, 5-HT3 / metabolism
  • Serotonin / metabolism
  • Serotonin 5-HT3 Receptor Agonists / pharmacology
  • Serotonin 5-HT3 Receptor Antagonists / chemistry
  • Serotonin 5-HT3 Receptor Antagonists / pharmacology*

Substances

  • Antidepressive Agents
  • Biguanides
  • N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide
  • Quinoxalines
  • Receptors, Serotonin, 5-HT3
  • Serotonin 5-HT3 Receptor Agonists
  • Serotonin 5-HT3 Receptor Antagonists
  • Fluoxetine
  • Serotonin
  • 1-(3-chlorophenyl)biguanide